Clinical trials: Acquired Immune Deficiency Syndrome
Healthy
A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
The purpose of this study is to evaluate the single-dose pharmacokinetics and pivotal bioequivalence of Darunavir (DRV) 800 milligram (mg), Emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 10 mg when administered as a…
- Trial name
- NCT02578550
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC), Emtricitabine/tenofovir alafenamide FDC, Darunavir
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
HIV/AIDS
M-Suubi: A Multi-Level Integrated Intervention to Reduce the Impact of HIV Stigma
M-Suubi, a three arm cluster randomized study will examine the effects and cost-effectiveness of a multi-level intervention on HIV viral suppression among 840 adolescents living with HIV (ALHIV) enrolled in 42 secondary schools…
- Trial name
- NCT05307250
- Testing
- Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE, Multiple Family Groups for HIV stigma reduction (MFG-HIVSR) plus FEE plus Group-based stigma reduction for educators (GED-HIVSR)., Bolstered Standard of Care (BSOC)
- Where
- Uganda
- Volunteers
- 1,851 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
HPV - Anogenital Human Papilloma Virus Infection, HSIL, High Grade Squamous Intraepithelial Lesions
E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM
This study evaluates the positive and negative predictive value of E6/E7 mRNA expression for anal HSIL and its capacity to predict incident HSIL in HIV + MSM. We also analyse the cost-effectiveness of this new screening strategy.
- Conditions
- HPV - Anogenital Human Papilloma Virus Infection, HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer, Hiv
- Trial name
- ELAVI-67 (NCT03357991)
- Where
- Spain
- Volunteers
- 355 people
- Sponsor
- Hospital Universitari de Bellvitge
HIV Disease
Therapy to Elevate CD4 Counts in HIV-1 Disease
For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment for patients who have inherited alpha-1-proteinase inhibitor deficiency.
- Trial name
- NCT01370018
- Testing
- alpha-1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
HIV Infections, Kidney Disease
A Study of Zidovudine in HIV-Infected Patients With Kidney Problems
To determine how zidovudine (AZT) for the treatment of HIV infection is metabolized and excreted or eliminated in patients with infected or diseased kidneys.
- Trial name
- NCT00000685
- Testing
- Zidovudine
- Where
- 2 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Tuberculosis
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
To evaluate the methodology for rapidly determining the early bactericidal activity (EBA), tolerance, and pharmacokinetics of isoniazid and levofloxacin in the treatment of pulmonary tuberculosis (TB).
- Trial name
- NCT00000778
- Testing
- Isoniazid, Pyridoxine hydrochloride, Levofloxacin
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Video-Intervention to Inspire Treatment Adherence for Life for Adolescents
This a two-arm randomized controlled trial whose objective is to explore the impact of VITAL Start for Adolescents (VS4A), a video-based antiretroviral treatment (ART) adherence intervention, on a range of implementation and…
- Trial name
- VS4A (NCT07064785)
- Testing
- Video-based ART adherence counseling, Standard of Care (SOC)
- Where
- 32 sites in Malawi
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Hiv
Evaluation of Long-Acting Injectable (LAI) and Teen Clubs in Adolescents (ATTUNE).
This is a 2-stage study assessing the effect of peer navigation (support from peers) and long-acting injectable antiretroviral therapy (ART) on viral suppression and retention in care among adolescents living with HIV and…
- Trial name
- ATTUNE (NCT06721078)
- Testing
- Peer navigation effectiveness
- Where
- 12 sites in South Africa
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Africa Health Research Institute
Infection, Human Immunodeficiency Virus, HIV Infections
GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
Human immuno deficiency virus 1 (HIV-1) infections continues to be a serious health threat throughout the world and development of medicines with new mechanism of action have an important role to play.
- Trial name
- NCT03231943
- Testing
- GSK3640254
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection, AIDS
Staccato: A Trial of CD4 Guided Treatment Interruption, Compared to Continuous Treatment, for HIV Infection
Treatment of HIV repairs the immune system, but continuous treatment is expensive and causes side effects. Would it not be better to treat intermittently, e.g.
- Trial name
- NCT00113126
- Testing
- Treatment interruption
- Where
- Switzerland
- Volunteers
- 526 people
- Sponsor
- University Hospital, Geneva
HIV - Human Immunodeficiency Virus
HIV Prevention With PrEP Among People on Opioid Replacement Therapy
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta…
- Trial name
- OAT-PrEP (NCT07160075)
- Testing
- Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs
- Where
- 6 sites in Canada
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Cara Spence
HIV Infections
A Mindfulness Based Approach to HIV Treatment Side Effects
We are exploring the effect that an 8 week stress reduction program based in mindfulness practices will have on the experience of medication side effects reported by HIV-infected men and women taking antiretroviral therapy.
- Trial name
- NCT00312936
- Testing
- Mindfulness-based Stress Reduction (MBSR)
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
Human Immunodeficiency Virus
Improving TelePrEP Initiation and Retention Outcomes in the US: The MISTR+ Study
This study uses a rapid randomized controlled trial (RCT) design to examine HIV pre-exposure prophylaxis (PrEP) delivered through telehealth.
- Trial name
- NCT07821671
- Testing
- No Marginal Cost Interventions, Low-Marginal Cost Interventions, Standard of Care
- Where
- United States
- Volunteers
- 223,165 people
- Sponsor
- Emory University
HIV, Mental Health
Social Contact-Based Brief Video Interventions To Reduce Stigma and ImproVe Engagement in HIV Prevention and Care and Mental Health Care for Youth Living With and Vulnerable to HIV
HIV stigma, poverty, and racism contribute to high rates of mental health problems and impede treatment for young sexually minoritized men living with and vulnerable to HIV.
- Trial name
- STRIVE (NCT07851077)
- Testing
- Brief Videos for HIV Stigma
- Volunteers
- 3,900 people, healthy volunteers welcome
- Sponsor
- City University of New York, School of Public Health
AIDS-Related-Primary Central Nervous System Lymphoma
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
This study will investigate the use of chemotherapy plus highly active antiretroviral therapy (HAART) in patients with Acquired Immunodeficiency Syndrome (AIDS)-related primary brain lymphoma.
- Trial name
- NCT00267865
- Testing
- Methotrexate, Rituximab, Leucovorin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Infection, Human Immunodeficiency Virus
Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir
This study is a single-center, randomized, open-label, two cohorts, 3-way cross-over design in 36 subjects to assess the oral bioavailability of four new cabotegravir (CAB) sodium salt tablet formulations relative to the current…
- Trial name
- NCT02345707
- Testing
- Cabotegravir 30 mg current formulation, Cabotegravir 30 mg micronized new formulation 500 M, Cabotegravir 30 mg unmicronized new formulation 500 U
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV/AIDS
MyPEEPS LITE Trial
This study will use community-informed advertisements and messages through electronic methods to recruit and retain a large (N=3,200), diverse national sample of high-risk young men who have sex with men (YMSM) and non-binary…
- Trial name
- NCT06741631
- Testing
- MyPEEPS Mobile
- Where
- 2 sites in United States
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Columbia University
Nicotine Dependence
Varenicline for Nicotine Dependence Among Those With HIV/AIDS
Among people diagnosed with HIV/AIDS, the widespread use of highly active antiretroviral therapy (HAART) has greatly improved survival rates and changed the leading causes of death, from AIDS-related diseases to cardiovascular…
- Trial name
- NCT01710137
- Testing
- Varenicline, Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- University of Pennsylvania
Ebola, HIV/AIDS
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
Ebola and HIV are found predominately in the same regions of the world and countries in sub-Saharan Africa are most affected by both diseases. For Ebola, no approved therapies exist.
- Trial name
- RemTLAR (NCT04385719)
- Testing
- Remdesivir
- Where
- Uganda
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Makerere University
AIDS-related Kaposi's Sarcoma
A Study of Selumetinib in Patients With Kaposi's Sarcoma
Cancer is a leading cause of death in individuals living with human immunodeficiency virus (HIV), and Kaposi's sarcoma (KS) remains the commonest HIV-associated cancer.
- Trial name
- SCART (NCT01752569)
- Testing
- Selumetinib
- Where
- 6 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.